v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Cash Flows From Operating Activities    
Net income $ 879,000 $ 1,007,000
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 245,000 196,000
Amortization of deferred financing fees 26,000
Stock-based compensation 8,000 24,000
Deferred taxes 339,000
Asset impairment - lab supplies 198,000
Lab supplies write-off 217,000
Change in fair value of note payable (18,000)
Amortization on operating lease right of use asset 216,000 193,000
Other changes in operating assets and liabilities:    
Accounts receivable (662,000) 1,313,000
Other current assets (440,000) (227,000)
Accounts payable 327,000 (409,000)
Accrued salaries and bonus (934,000) (176,000)
Other accrued expenses 231,000 (401,000)
Operating lease liabilities (263,000) (185,000)
Other long-term liabilities 218,000 214,000
Net cash provided by operating activities 381,000 1,755,000
Cash Flows From Investing Activity    
Purchase of property and equipment (198,000) (201,000)
Net cash used in investing activities (198,000) (201,000)
Cash Flows From Financing Activities    
Payments made on note payable (2,500,000)
Series C conversion costs (13,000)
Net cash used in financing activities (2,513,000)
Net increase (decrease) in cash and cash equivalents 183,000 (959,000)
Cash and cash equivalents – beginning 2,505,000 1,461,000
Cash and cash equivalents – ending $ 2,688,000 $ 502,000